Findings show potential for new lipid-based delivery formulations as a platform technology for immunizationPhiladelphia, PA, ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.

VistaShares Co-Founder Jon McNeill discusses the VistaShares Artificial Intelligence Supercycle ETF (ticker: AIS). He explains a supercylcle, which he says currently includes AI, electrification ...